Literature DB >> 15615740

Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma.

A Luksch1, G Rainer, D Koyuncu, P Ehrlich, T Maca, M E Gschwandtner, C Vass, L Schmetterer.   

Abstract

AIM: To investigate the effects of oral nimodipine on ocular haemodynamic parameters and colour contrast sensitivity in patients with normal tension glaucoma (NTG).
DESIGN: The study was performed in a randomised, placebo controlled, double masked, crossover design. PARTICIPANTS: Nimodipine (60 mg) or placebo was administered to 14 consecutive NTG patients.
METHODS: The effects or oral nimodipine or placebo on ocular and systemic haemodynamic parameters and colour contrast sensitivity along the tritan axis were studied two hours after administration. Optic nerve head blood flow (ONHBF) and choroidal blood flow (CHBF) were assessed with laser Doppler flowmetry. Ocular fundus pulsation amplitude (FPA) was measured with laser interferometry. Colour contrast sensitivity (CCS) was determined along the tritan colour axis. MAIN OUTCOME MEASURES: ONHBF, CHBF, FPA, intraocular pressure and CCS were assessed in patients with NTG.
RESULTS: Mean ocular FPA increased by 14% (SD 14%) (p = 0.0008), ONHBF by 18% (SD 16%) (p = 0.0031), and CHBF by 12% (SD 14%) (p<0.001) after administration of nimodipine. Nimodipine also decreased the threshold of colour contrast sensitivity along the tritan colour axis (-14% (SD 12%); p = 0.048). However, individual changes in FPA, ONHBF, or CHBF were not correlated with changes in threshold of CCS along the tritan colour axis.
CONCLUSIONS: The results indicate that nimodipine increases ONH and choroidal blood flow in NTG patients and improves CCS. The latter effect does not, however, seem to be a direct consequence of the blood flow improvement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15615740      PMCID: PMC1772476          DOI: 10.1136/bjo.2003.037671

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  37 in total

1.  Laser Doppler flowmetry in the optic nerve.

Authors:  C E Riva; S Harino; B L Petrig; R D Shonat
Journal:  Exp Eye Res       Date:  1992-09       Impact factor: 3.467

2.  Peripheral contrast sensitivity in glaucoma and ocular hypertension.

Authors:  F Falcão-Reis; E O'Donoghue; R Buceti; R A Hitchings; G B Arden
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

3.  Optic nerve head circulation after topical calcium channel blocker.

Authors:  P A Netland; G T Feke; S Konno; D G Goger; N Fujio
Journal:  J Glaucoma       Date:  1996-06       Impact factor: 2.503

4.  Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker.

Authors:  P A Netland; C L Grosskreutz; G T Feke; L J Hart
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

5.  Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon.

Authors:  K Darton; C M Black
Journal:  Br J Rheumatol       Date:  1991-06

6.  An endothelin-1 induced model of optic nerve ischemia in the rabbit.

Authors:  S Orgül; G A Cioffi; D J Wilson; D R Bacon; E M Van Buskirk
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-08       Impact factor: 4.799

7.  Calcium channel blockers in the management of low-tension and open-angle glaucoma.

Authors:  P A Netland; N Chaturvedi; E B Dreyer
Journal:  Am J Ophthalmol       Date:  1993-05-15       Impact factor: 5.258

8.  Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma.

Authors:  A Sawada; Y Kitazawa; T Yamamoto; I Okabe; K Ichien
Journal:  Ophthalmology       Date:  1996-02       Impact factor: 12.079

9.  Choroidal blood flow in the foveal region of the human ocular fundus.

Authors:  C E Riva; S D Cranstoun; J E Grunwald; B L Petrig
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-12       Impact factor: 4.799

10.  Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases.

Authors:  A Z Gaspar; J Flammer; P Hendrickson
Journal:  Eur J Ophthalmol       Date:  1994 Jan-Mar       Impact factor: 1.922

View more
  8 in total

1.  Nimodipine Ophthalmic Formulations for Management of Glaucoma.

Authors:  Doaa Nabih Maria; Abd-Elgawad Helmy Abd-Elgawad; Osama Abd-Elazeem Soliman; Marwa Salah El-Dahan; Monica M Jablonski
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

Review 2.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

3.  Glutamate-induced internalization of Ca(v)1.3 L-type Ca(2+) channels protects retinal neurons against excitotoxicity.

Authors:  Fengxia Mizuno; Peter Barabas; David Krizaj; Abram Akopian
Journal:  J Physiol       Date:  2010-02-01       Impact factor: 5.182

Review 4.  Glaucomatous optic neuropathy management: the role of neuroprotective agents.

Authors:  Marianne L Shahsuvaryan
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

5.  Systems genetics identifies a role for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility.

Authors:  Sumana R Chintalapudi; Doaa Maria; Xiang Di Wang; Jessica N Cooke Bailey; Pirro G Hysi; Janey L Wiggs; Robert W Williams; Monica M Jablonski
Journal:  Nat Commun       Date:  2017-11-24       Impact factor: 14.919

6.  Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects.

Authors:  Hui-Ping Duan; Rong Liu
Journal:  Drug Des Devel Ther       Date:  2022-03-21       Impact factor: 4.162

7.  Current primary open-angle glaucoma treatments and future directions.

Authors:  Gabriel Beidoe; Shaker A Mousa
Journal:  Clin Ophthalmol       Date:  2012-10-23

Review 8.  New directions in the treatment of normal tension glaucoma.

Authors:  Brian J Song; Joseph Caprioli
Journal:  Indian J Ophthalmol       Date:  2014-05       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.